Skip to main content

Table 1 The response of primary and metastatic lesions to gefitinib in responders

From: Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer

Site

No. of patients

No. improved

No. of patients with target lesion

Average tumor shrinkage of target lesion (%, mean ± SD)

Primary lesion

27

27

21

46.5 ± 19.4

Metastatic lesion

    

   Intrapulmonary

12

12

9

73.8 ± 30.6

   Liver

4

4

3

47.3 ± 21.6

   CNS

4

4

2

65.0 ± 21.2

   Bone

8

0

  

   Pleural effusion

6

5

  

   Others

2

2

  
  1. CNS, central nervous system